Document qapo2xyRXb77r1zEZ4K3dJxNq

BACK TO MAIN 3M Comments Submitted to the EPA Science Advisory Board Perfluorooctanoic Acid Human Health Risk Assessment Review Panel (PFOA Review Panel) Click on Study Title to View Report John A. Moore, D.V.M., DABT (Hollyhouse, Inc.), Comments to the PFOA Review Panel regarding Points of Departure for PFOA Risk Assessment, February 10, 2005 Butenhoff, J.L., et al., "Characterization of Risk for General Population Exposure to Perfluorooctanoate," Regulatory Toxicology and Pharmacology 39 (2004) 363-380, April 16, 2004 Geary Olsen and Larry Zobel (3M), Comments of the 3M Company to the EPA Sci ence Advisory Board PFOA Review Panel, February 10, 2005 Joseph V. Rodricks, Ph.D. (Environ Corp.), Comments to the PFOA Review Panel, February 11, 2005 John L. Butenhoff, Ph.D., Geary Olsen, DVM, Ph.D., and Larry Zobel, M.D., Ph.D., "Additional Comments of the 3M Company to the EPA Science Advisory Board PFOA Review Panel," April 18, 2005 Larry Zobel, M.D., M.P.H. (3M), Letter commenting on PFOA Review Panel's June 27, 2005 draft report, June 29, 2005 Larry Zobel, M.D., M.P.H. (3M), Letter submitting Pathology Working Group Report on Mammary Tumors in Chronic Study of PFOA, June 27, 2005 Hardisty, J.F., Experimental Pathology Laboratories, Inc., "Pathology Peer Review and Pathology Working Group Review of Mammary Glands from a Chronic Feeding Study in Rats with PFOA," EPL Project No. 129-060, June 17, 2005